Alla studier
RekryteringFAS3INTERVENTIONELL

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

This research study is looking at a new medicine called nipocalimab for adults who have a condition called generalised myasthenia gravis, or gMG. gMG causes muscles to become weak and tired easily. The main aim of the study is to find out how well nipocalimab works compared to a 'dummy' medicine (placebo) and whether it is safe to use. The study also includes a smaller part to see how the body handles nipocalimab when it's given as an injection just under the skin, compared to giving it through a drip into a vein. This helps researchers understand the best way to give the medicine. Participants will either receive the active medicine or the placebo, and their health and symptoms will be carefully monitored throughout the study.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
Janssen Forskning & Utveckling, LLC
Inskrivningsmål
199
Starta
15 jul 2021
Beräknad slutförande
30 mars 2029

Resultat

Resultat från denna studie

Publicerad Juli 2025

Resultaten har publicerats för denna studie.

Primärt resultat
Double-blind (DB) Phase: Average Change From Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score Over Weeks 22, 23, and 24
Average change from baseline over multiple timepoints (Weeks 22, 23, and 24) was reported in this outcome measure. The MG-ADL provided a rapid assessment of the participant's MG symptom severity of eight functions (talking, chewing, swallowing, breathing, impairment of ability to brush teeth or comb hair, impairment of ability to arise from a chair, double vision, eyelid droop) rated on a 4-point scale ranging from 0 (normal) to 3 (severe). MG-ADL total score was sum of 8 individual items, which ranging from 0 to 24. A higher score indicated greater symptom severity. Baseline was defined as the average of the screening and Day 1 total scores.
Fullständiga resultat i registret

Vad handlar denna studie om?

This research study is about a muscle weakness condition called generalised myasthenia gravis (gMG). If you have gMG, your body's immune system mistakenly attacks healthy connections between your nerves and muscles, leading to muscle weakness that can affect things like your eyes, face, throat, and limbs. This can make everyday activities quite challenging.

The study is testing a new medicine called nipocalimab. Researchers want to see if this medicine can help improve the symptoms of gMG and make a real difference to people's lives. To do this, they will compare nipocalimab to a 'dummy' treatment (called a placebo), which looks exactly like the real medicine but contains no active ingredients. This comparison helps them understand if any changes are truly due to nipocalimab or might have happened anyway.

Another important part of this study is looking at how nipocalimab works when given in different ways. Some participants will receive the medicine through a drip into a vein, which is a common way to give medicines. Others will receive it as an injection just under the skin. This helps the researchers figure out the most effective and convenient way to deliver the medicine, which could be very helpful for future patients.

Viktiga punkter

  • This study is testing a new medicine, nipocalimab, for generalised myasthenia gravis (gMG).
  • It aims to see if nipocalimab is safe and effective compared to a dummy treatment (placebo).
  • The medicine might be given through a drip or as an injection under the skin.
  • Participation involves regular clinic visits for treatments, tests, and symptom checks.
  • You will be closely monitored, and your care team will track your health.
  • You can withdraw from the study at any point without affecting your regular medical care.

Vem kan vara berättigad?

To join this study, adults must have a confirmed diagnosis of generalised myasthenia gravis (gMG) that affects various muscles in their body, not just a mild form. You would need to be experiencing specific levels of muscle weakness in your daily activities according to a special scale.

The study also has some rules about other health conditions. For example, you can't have certain problems with your immune system or a history of a 'myasthenia crisis' recently. If you've had surgery to remove your thymus gland, there's a time limit for when you can join after that surgery. Also, if you know you're allergic to nipocalimab or its ingredients, you wouldn't be able to take part.

For women who could become pregnant, special pregnancy tests are required, and male participants must agree not to donate sperm during the study and for a period after. If you're considering the part of the study where the medicine is given as an injection under the skin, you'd need suitable skin on your tummy for the injections and be able to keep your regular medications for gMG stable for the first few weeks.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Do I have a confirmed diagnosis of generalised myasthenia gravis (gMG)?
  2. Are my gMG symptoms affecting my daily activities to a certain degree?
  3. Have I had a thymectomy (surgery to remove my thymus gland) more than a year ago?
  4. Do I have any specific immune problems or allergies that might stop me from joining?
  5. Am I willing to attend regular clinic visits and follow the study instructions?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part in this study, you'll be assigned to either receive the new medicine, nipocalimab, or a placebo (a dummy medicine). You won't know which one you're getting, and neither will your study doctor. Depending on which group you're in, the medicine could be given through a drip into a vein or as an injection under your skin. This will involve regular visits to the study clinic for these treatments and check-ups.

Throughout the study, the research team will closely monitor your health, symptoms, and how you're feeling. This will involve various tests, blood samples, and questionnaires at regular visits. These visits are important for the team to understand how the medicine is working and to make sure you are safe. For some participants, there's a specific part of the study (called a substudy) where you'll receive injections under the skin. This will also involve keeping your current gMG medications, like steroids, at a steady dose for the first 8 weeks.

The total duration of your participation in the study will involve regular visits for treatment and assessments, followed by a period where your health is still monitored even after you stop receiving the study medicine. You will be given a detailed schedule of visits and procedures if you decide to take part, and you will always have the right to withdraw from the study at any time.

Potentiella risker och fördelar

Taking part in a clinical trial has potential benefits and risks. You might benefit from receiving a new medicine that could improve your gMG symptoms, and you'll be closely monitored by a healthcare team. However, nipocalimab is still being tested, which means its full effects and side effects aren't completely known yet. You might experience side effects from the medicine, or it might not work for you. There's also a chance you could receive the placebo, which won't directly treat your gMG but will still involve clinic visits and procedures. As with any study, there's a small risk associated with blood draws and other tests. You have the right to stop taking part in the study at any time, for any reason, without it affecting your usual medical care.

Platser (112)

  • Neuromuscular Research Center and Clinic
    Verifierat postnummer
    Paradise Valley, USA· Rekrytering
  • HonorHealth Neurology
    Verifierat postnummer
    Scottsdale, USA· Avslutad
  • University of Southern California
    Verifierat postnummer
    Los Angeles, USA· Avslutad
  • Stanford Universitet
    Verifierat postnummer
    Palo Alto, USA· Avslutad
  • Care Access Research
    Verifierat postnummer
    Pasadena, USA· Rekrytering
  • University of Colorado Anschutz Medical Campus
    Verifierat postnummer
    Aurora, USA· Rekrytering
  • Yale New Haven-sjukhuset
    Verifierat postnummer
    New Haven, USA· Rekrytering
  • FM Clinical Research, LLC South Florida Neurology Associates, P. A.
    Verifierat postnummer
    Boca Raton, Förenta staterna· Rekrytering
  • University of Florida Health Jacksonville
    Verifierat postnummer
    Jacksonville, USA· Avslutad
  • Medsol Clinical Research Center Inc
    Verifierat postnummer
    Port Charlotte, USA· Rekrytering
  • University of South Florida
    Verifierat postnummer
    Tampa, USA· Rekrytering
  • Augusta University
    Verifierat postnummer
    Augusta, USA· Avslutad

Vanliga frågor

What is generalised myasthenia gravis (gMG)?

gMG is a condition where your body's immune system mistakenly attacks parts of your muscles, making them weak and tired easily, affecting many parts of your body.

Vad är nipocalimab?

Nipocalimab is a new medicine being tested to see if it can help improve the symptoms of gMG. It's not yet approved for general use.

Vad är en placebo?

A placebo is a 'dummy' treatment that looks like the actual medicine but doesn't contain any active ingredients. It helps researchers fairly compare the new medicine's effects.

Hur kommer medicinen att ges?

Depending on which group you're in, it could be given through a drip into your vein or as an injection just under your skin.

Kan jag lämna studien om jag ändrar mig?

Ja, du kan välja att lämna studien när som helst, av vilken anledning som helst, utan att det påverkar din medicinska vård.

Hur du får reda på mer

Studiekontakt

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Study of Nipocalimab Administered to Adults With Generaliz…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.